After many indications and successful minimally invasive surgery (MIS) in surgical specialties, medical equipment companies turned to surgical robots as the next major innovation.
These systems for robot-assisted surgery are increasing more and more, and interest in the world is increasing. Many companies at the forefront of this technology are emerging companies and small companies devoted to surgical robotic systems. In this way capital procurement is becoming increasingly important and vigorous in this field.
Surgical robotic systems are designed to solve the limitations still present in MIS procedures and to improve surgery. These systems exist for a range of indications, from general purpose systems shown in various general surgical procedures to specialized systems for orthopedic knee replacement surgery. Robot support surgery aims to increase accuracy and control in complicated procedures, but these robot systems are generally very expensive to obtain.
Scenery of surgical robot
The intense competition of surgical robots is large and diverse, and both large-scale multinational companies and small founder enter this space. Among these, Intuitive Surgical boasts the world's top surgical robot market since its first generation of Da Vinci system was approved by the FDA in 2000. Global competitors such as Meduitronic, Johnson & Johnson, Stryker have partnered with or obtained a surgical robot company to promote robot innovation and gain market share. However, most surgical robotic systems are being developed by small companies and start-ups that rely on financing and financing for continuous progress.
In the past year, several surgical robot players including Titan Medical, Medrobotics, Accuray announced financing through public and private placement. The largest deal supports CMR surgery, Corindus vascular robot, and Mazor robot. In September 2017, Mazor Robotics completed the private share of the 3 rd tranche at $ 40 million and announced a total of 72 million dollars. With this acquisition, Medtronic's total investment in Mazor was $ 125 million. Corinus Vascular Robotics announced a public offering in April 2018 and issued ordinary shares with total revenue of $ 533 million, CMR Surgical raised $ 100 million in Series B finance in June 2018. CMR will use this revenue to support the planned commercialization of its Versius system.
Improvements in surgical procedures through the use of robotics will increase the patient population suited for treatment and reduce complications and negative outcomes. As partnerships and funding in the surgical robotics market continues to support innovation, GlobalData believes that the competitive environment is more crowded and the market will continue to grow to support a wider range of surgical procedures and patients.